Telesis Bio Stock Earnings Per Share
Telesis Bio fundamentals help investors to digest information that contributes to Telesis Bio's financial success or failures. It also enables traders to predict the movement of Telesis Pink Sheet. The fundamental analysis module provides a way to measure Telesis Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Telesis Bio pink sheet.
Telesis |
Telesis Bio Company Earnings Per Share Analysis
Telesis Bio's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Telesis Bio Earnings Per Share | (30.42) X |
Most of Telesis Bio's fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Telesis Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
CompetitionAccording to the company disclosure, Telesis Bio has an Earnings Per Share of -30.42 times. This is 463.44% lower than that of the Health Care Equipment & Supplies sector and notably higher than that of the Health Care industry. The earnings per share for all United States stocks is notably higher than that of the company.
Telesis Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Telesis Bio's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Telesis Bio could also be used in its relative valuation, which is a method of valuing Telesis Bio by comparing valuation metrics of similar companies.Telesis Bio is currently under evaluation in earnings per share category among its peers.
Telesis Fundamentals
| Return On Equity | -1.48 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (2.53) % | ||||
| Operating Margin | (6.76) % | ||||
| Current Valuation | 61.1 M | ||||
| Shares Outstanding | 1.77 M | ||||
| Shares Owned By Insiders | 37.90 % | ||||
| Shares Owned By Institutions | 32.97 % | ||||
| Number Of Shares Shorted | 29.7 K | ||||
| Price To Earning | 71.32 X | ||||
| Price To Book | 1.11 X | ||||
| Price To Sales | 0.29 X | ||||
| Revenue | 27.51 M | ||||
| Gross Profit | 15.6 M | ||||
| EBITDA | (31.05 M) | ||||
| Net Income | (47.72 M) | ||||
| Cash And Equivalents | 654.75 M | ||||
| Cash Per Share | 8.70 X | ||||
| Total Debt | 34.38 M | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 5.93 X | ||||
| Book Value Per Share | (11.59) X | ||||
| Cash Flow From Operations | (34.67 M) | ||||
| Short Ratio | 0.42 X | ||||
| Earnings Per Share | (30.42) X | ||||
| Target Price | 4.0 | ||||
| Number Of Employees | 101 | ||||
| Beta | 1.76 | ||||
| Market Capitalization | 5.73 M | ||||
| Total Asset | 70.41 M | ||||
| Retained Earnings | (161.47 M) | ||||
| Working Capital | 22.17 M | ||||
| Current Asset | 3.28 M | ||||
| Current Liabilities | 16.98 M | ||||
| Net Asset | 70.41 M |
Pair Trading with Telesis Bio
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Telesis Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Telesis Bio will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Nucor Corp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nucor Corp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nucor Corp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nucor Corp to buy it.
The correlation of Nucor Corp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nucor Corp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nucor Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nucor Corp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Telesis Pink Sheet
If you are still planning to invest in Telesis Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Telesis Bio's history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |